Instil Bio Inc
NASDAQ:TIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jason Furniture Hangzhou Co Ltd
SSE:603816
|
CN |
|
S
|
Suraj Estate Developers Ltd
NSE:SURAJEST
|
IN |
|
Mastek Ltd
NSE:MASTEK
|
IN |
|
COSCO India Ltd
BSE:530545
|
IN |
|
Bollore SE
OTC:BOIVF
|
FR |
|
MI Ming Mart Holdings Ltd
HKEX:8473
|
HK |
|
Katakura & Co-op Agri Corp
TSE:4031
|
JP |
|
Medusa Mining Ltd
ASX:MML
|
AU |
|
Matterport Inc
NASDAQ:MTTR
|
US |
|
Nextera Energy Partners LP
NYSE:NEP
|
US |
|
S
|
Solarvest Holdings Bhd
KLSE:SLVEST
|
MY |
|
Group Five Pipe Saudi Ltd
SAU:9523
|
SA |
|
Inageya Co Ltd
TSE:8182
|
JP |
Instil Bio Inc
Intangible Assets
Instil Bio Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Instil Bio Inc
NASDAQ:TIL
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Intangible Assets
$52.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Intangible Assets
$17B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Intangible Assets
$22.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Intangible Assets
$424.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Intangible Assets
$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Instil Bio Inc
Glance View
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 412 full-time employees. The company went IPO on 2021-03-19. The firm is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. The company is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. The company is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.
